MedTrace Logo

The Detection of Cell-in-cell Structure (CICs) in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy

NCT05642104 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 175

Last updated 2022-12-08

No results posted yet for this study

Summary

Breast cancer is the most common malignant tumor in women worldwide and neoadjuvant therapy has been the standard care for local advanced breast cancer. Moreover, neoadjuvant therapy undoubtedly provides an ideal model to evaluate the response to therapy. Cell-in-cell structures (CICs) refer to the presence of one or more cells inside host cell, which generally leads to the death of inner cells. Notably, established evidences indicated that CICs were present in breast cancer and tend to impact patient survival. However, whether CICs profile could predict efficacy of therapy remains unclear. In this prospective cohort study, the CICs number and profile will be detected in tumor tissue before and after the neoadjuvant therapy. Then the association between CICs number including dynamic changing and response rate will be explored.

Conditions

  • Breast Neoplasms

Interventions

DRUG

Neoadjuvant therapy

all procedures is in accordance with international guidelines and domestic expert consensus on breast cancer.

Sponsors & Collaborators

  • Beijing Shijitan Hospital, Capital Medical University

    lead OTHER

Principal Investigators

  • Hongyan Huang, PHD · Beijing Shijitan Hospital, Capital Medical University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2023-10-01
Completion
2024-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05642104 on ClinicalTrials.gov